(+98)21-26413024

(+98)21-26411650

  • Home
  • weblog
  • FDA approves Interrmezzo for insomnia

FDA approves Interrmezzo for insomnia

Share
FDA approves Interrmezzo for insomnia

This is the first time the FDA has approved a drug for this condition. Intermezzo should only be used when a person has at least four hours of bedtime remaining. It should not be taken if alcohol has been consumed or with any other sleep aid.

Insomnia is a common condition in which a person has trouble falling or staying asleep. It can range from mild to severe, depending on how often it occurs and for how long. Insomnia can cause excessive daytime sleepiness and lack of energy. It also can make a person feel anxious, depressed, or irritable. People with insomnia may have trouble focusing on tasks, paying attention, learning, and remembering.

Zolpidem tartrate was first approved in the United States in 1992 as the drug Ambien. Intermezzo is a lower dose formulation of zolpidem. The recommended and maximum dose of Intermezzo is 1.75 milligrams for women and 3.5 mg for men, taken once per night. The recommended dose for women is lower because women clear zolpidem from the body at a lower rate than men.

Comments

?Your opinion


captcha

FDA approves combination therapy Juvisync

The FDA has recently become aware of the potential for statins to increase ...

FDA Approves Combivent Respimat Inhalation Spray

Combivent Respimat is a suitable alternative for patients who are currently ...

FDA approves Interrmezzo for insomnia

This is the first time the FDA has approved a drug for this condition. ...

FDA approves first generic version of cholesterol-lowering drug Lipitor

The U.S. Food and Drug Administration today approved the first generic ...